The estimated Net Worth of Frank Litvack is at least $695 mil dollars as of 14 August 2023. Dr Litvack owns over 20,748 units of Capricor Therapeutics Inc stock worth over $575,306 and over the last 10 years he sold CAPR stock worth over $0. In addition, he makes $120,000 as Exec. Chairman at Capricor Therapeutics Inc.
Sign up
Dr FACC CAPR stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Capricor Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 20,748 units of CAPR stock worth $28,840 on 14 August 2023.
The largest trade he's ever made was exercising 154,543 units of Capricor Therapeutics Inc stock on 3 January 2022 worth over $214,815. On average, Dr trades about 13,523 units every 42 days since 2015. As of 14 August 2023 he still owns at least 137,633 units of Capricor Therapeutics Inc stock.
You can see the complete history of Dr Litvack stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Frank Isaac Litvack M.D., FACC biography
Dr. Frank Isaac Litvack M.D., FACC is the Exec. Chairman at Capricor Therapeutics Inc.
What is the salary of Dr FACC?
As the Exec. Chairman of Capricor Therapeutics Inc, the total compensation of Dr FACC at Capricor Therapeutics Inc is $120,000. There are 5 executives at Capricor Therapeutics Inc getting paid more, with Karen G. Krasney having the highest compensation of $346,750.
How old is Dr FACC?
Dr FACC is 64, he's been the Exec. Chairman of Capricor Therapeutics Inc since . There are 6 older and 11 younger executives at Capricor Therapeutics Inc. The oldest executive at Capricor Therapeutics Inc is Louis Grasmick, 90, who is the Independent Director.
What's Dr FACC's mailing address?
Frank's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121.
Insiders trading at Capricor Therapeutics Inc
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... y Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
What does Capricor Therapeutics Inc do?
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
What does Capricor Therapeutics Inc's logo look like?
Complete history of Dr Litvack stock trades at Capricor Therapeutics Inc
Capricor Therapeutics Inc executives and stock owners
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Karen G. Krasney,
Exec. VP, Gen. Counsel & Sec. -
Anthony J. Bergmann M.B.A.,
CFO & Corp. Treasurer -
Karen Krasney,
Executive Vice President, General Counsel -
Linda Marban,
President, Chief Executive Officer, Director -
Dr. Linda Marbán,
Co-Founder, Pres, CEO & Director -
Dr. Frank Isaac Litvack FACC, M.D.,
Exec. Chairman -
Dr. Frank Isaac Litvack M.D., FACC,
Exec. Chairman -
Joshua Kazam,
Director -
David Musket,
Independent Director -
Louis Manzo,
Independent Director -
Louis Grasmick,
Independent Director -
George Dunbar,
Independent Director -
Earl Collier,
Independent Director -
Deborah Ascheim,
Chief Medical Officer -
Rachel Smith,
Vice President - Research & Development -
Luis Rodriguez-Borlado,
Vice President - Regenerative Therapies -
Houman Hemmati,
Vice President - Medical & Clinical Development, New Therapies -
Thomas Copmann,
Vice President - Regulatory Affairs and Drug Development -
Anthony Bergmann,
Chief Financial Officer, Principal Accounting Officer -
Frank Litvack,
Independent Executive Chairman of the Board -
Catherine Lee Kelleher,
Consultant -
Dr. Deborah D. Ascheim,
Consultant -
Dr. Eduardo Marbán,
Co-Founder & Chairman of Scientific Advisory Board -
Leland Gershell,
CHIEF FINANCIAL OFFICER -
John Edward A.Edward St. Jo...,
-
Sinai Medical Center Cedars,
10% owner -
Xavier Avat,
-
Philip J Gotwals,
-
Paul Gisbert Auwaerter,
-
Eduardo Marban,
10% owner -
Gregory W Schafer,
Director -
Mike Kelliher,
-
Karimah Es Sabar,